NIKKEI 225
38,062.84 +434.36 (+1.15%) HANG SENG
17,626.75 +342.21 (+1.98%) CRUDE OIL
83.90 +0.33 (+0.39%) GOLD FUTURES
2,348.10 +5.60 (+0.24%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,309.55 -7.72 (-0.02%)
Bio-Rad Laboratories, Inc. (BUWA.DE)
| Previous close | 516.60 |
| Open | 511.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 511.00 - 516.60 |
| 52-week range | 444.20 - 700.00 |
| Volume | |
| Avg. volume | 1 |
| Market cap | 15.81B |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.22 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireBio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Simply Wall St.Bio-Rad Laboratories (NYSE:BIO shareholders incur further losses as stock declines 14% this week, taking three-year losses to 53%
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Bio-Rad Laboratories...
GlobeNewswireOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the c
